Pharmaceuticals, Biotechnology & Life Sciences

Insider buying surges as CFO of MoonLake buys 354K shares amid FDA‑positive news on Sonelokimab, signaling confidence and a potential rebound from $5.95 low.

Maze Therapeutics insiders buy low at $10.42 and sell near $40, signaling cautious optimism and strategic hedging for future milestones.

Insider sales at Praxis Precision Medicines signal short‑term liquidity moves, not loss of faith—while a $575 M public offering and strong cash reserves support long‑term upside.

Insider sale by NIGON RICHARD in bullish Celcuity stock: a tactical rebalancing, not a red flag—watch derivative‑to‑equity moves and clinical pipeline for insights.

Insider buying surge at SELLAS Life Sciences: over 900,000 shares bought by senior execs signals confidence, yet market sentiment lags—watch FDA milestones and earnings for a potential rally.

Insider selling spurs debate: Acumen execs liquidate shares amid volatility, yet 10b5‑1 plans and a 52‑week low hint at a value play for cautious investors.

Arcus insider selling: CEO Terry Rosen’s recent “charitable gift” stock sale signals cautious portfolio shifts and impacts investor sentiment on the biotech’s future.

Neumora’s insiders buy 4.5 M shares of stock‑options, signaling confidence in its brain‑therapy pipeline and a bullish outlook for the neuro‑pharma sector.

Insight into COO Margaret Horn’s 10b5‑1 trades at Revolution Medicines and what it means for investors and the company’s future.

Vericel insider trades reveal a disciplined buy‑sell‑exercise pattern, boosting confidence in the COO’s long‑term belief in the company’s regenerative‑medicine growth.